TapewireFind a company

person · Reporting owner

Shenouda Maged

Disclosed activity across 2 companies

Tapewire entity
71429
SEC CIK
0001658369

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
GridAI Technologies Corp.AZRX · Entity 7534Director · CHIEF FINANCIAL OFFICERDecember 28, 2018January 02, 2019
RELMADA THERAPEUTICS, INC.RLMD · Entity 5498Chief Financial OfficerSeptember 09, 2026September 11, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

GridAI Technologies Corp.

Report date December 28, 2018 · Filed January 02, 2019

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect62,500 Reported balance After 2018-12-28 transaction · row 1
1 source row

Row 1 · 2018-12-28 · Purchase · Acquired 20,000 · Balance 62,500

RELMADA THERAPEUTICS, INC.

Report date September 09, 2026 · Filed September 11, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect1,000,000 Ending reported balance After 2026-09-10 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-09-09 · Purchase · Acquired 120,200 · Balance 920,200

F1: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.

F2: Purchase prices range from $4.16 to $4.20 per share, inclusive.

Row 2 · 2026-09-10 · Purchase · Acquired 79,800 · Balance 1,000,000

Filing footnotes · ownership attribution and instrument terms

F1: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.

F2: Purchase prices range from $4.16 to $4.20 per share, inclusive.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
September 10, 2026 Filed Sep 11, 2026 11:30 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 PurchaseCommon Stock 79,800 $4.25 $339,150.00
Disclosure

SEC source: 0001213900-26-098970 · ownership.xml · nonDerivative · entry 2

Shenouda Maged · CIK 0001658369 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,000,000

Read SEC document
September 09, 2026 Filed Sep 11, 2026 11:30 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 PurchaseCommon Stock 120,200 $4.20 $504,840.00
Disclosure

SEC source: 0001213900-26-098970 · ownership.xml · nonDerivative · entry 1

Shenouda Maged · CIK 0001658369 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 920,200

F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.

F2 · price: Purchase prices range from $4.16 to $4.20 per share, inclusive.

Read SEC document
December 15, 2025 Filed Dec 16, 2025 09:30 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 PurchaseCommon Stock 11,665 $4.12 $48,059.80
Disclosure

SEC source: 0001213900-25-121973 · ownership.xml · nonDerivative · entry 1

Shenouda Maged · CIK 0001658369 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 800,000

Read SEC document
December 12, 2025 Filed Dec 16, 2025 09:30 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 GrantStock Appreciation Rights · Derivative 828,000 $0.00 Strike: $4.06 $0.00
Disclosure

SEC source: 0001213900-25-121973 · ownership.xml · derivative · entry 2

Shenouda Maged · CIK 0001658369 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 828,000

Underlying: Common Stock · 828,000 shares

Expires 2035-12-12

F1 · derivative.exercise_date: The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026.

Read SEC document
November 05, 2025 Filed Nov 6, 2025 07:30 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 PurchaseCommon Stock 500,000 $2.20 $1,100,000.00
Disclosure

SEC source: 0001213900-25-106836 · ownership.xml · nonDerivative · entry 1

Shenouda Maged · CIK 0001658369 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 788,335

Read SEC document
June 26, 2025 Filed Jun 30, 2025 19:29 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 GrantStock Option (right to buy) · Derivative 600,000 $0.00 Strike: $0.67 $0.00
Disclosure

SEC source: 0001213900-25-059869 · ownership.xml · derivative · entry 1

Shenouda Maged · CIK 0001658369 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 600,000

Underlying: Common Stock · 600,000 shares

Expires 2035-06-26

F1 · derivative.exercise_date: The options vest in 16 equal quarterly installments commencing on September 26, 2025.

Read SEC document
May 20, 2025 Filed May 20, 2025 18:03 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 PurchaseCommon Stock 60,000 $0.52 $31,422.00
Disclosure

SEC source: 0001213900-25-046087 · ownership.xml · nonDerivative · entry 3

Shenouda Maged · CIK 0001658369 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 288,335

F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.

F4 · price: Purchase prices range from $0.4998 to $0.5396 per share, inclusive.

Read SEC document
May 19, 2025 Filed May 20, 2025 18:03 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 PurchaseCommon Stock 90,000 $0.49 $43,686.00
Disclosure

SEC source: 0001213900-25-046087 · ownership.xml · nonDerivative · entry 2

Shenouda Maged · CIK 0001658369 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 228,335

F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.

F3 · price: Purchase prices range from $0.4493 to $0.4998 per share, inclusive.

Read SEC document
May 16, 2025 Filed May 20, 2025 18:03 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 PurchaseCommon Stock 50,000 $0.44 $22,100.00
Disclosure

SEC source: 0001213900-25-046087 · ownership.xml · nonDerivative · entry 1

Shenouda Maged · CIK 0001658369 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 138,335

F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.

F2 · price: Purchase prices range from $0.4229 to $0.4674 per share, inclusive.

Read SEC document
September 11, 2024 Filed Sep 11, 2024 17:46 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 PurchaseCommon Stock 24,120 $2.95 $71,154.00
Disclosure

SEC source: 0001213900-24-077792 · ownership.xml · nonDerivative · entry 3

Shenouda Maged · CIK 0001658369 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 88,335

F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.

F4 · price: Purchase prices range from $2.79 to $3.05 per share, inclusive.

Read SEC document
September 10, 2024 Filed Sep 11, 2024 17:46 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 PurchaseCommon Stock 21,118 $2.73 $57,652.14
Disclosure

SEC source: 0001213900-24-077792 · ownership.xml · nonDerivative · entry 2

Shenouda Maged · CIK 0001658369 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,215

F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.

F3 · price: Purchase prices range from $2.70 to $2.75 per share, inclusive.

Read SEC document
September 09, 2024 Filed Sep 11, 2024 17:46 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 PurchaseCommon Stock 8,194 $2.55 $20,894.70
Disclosure

SEC source: 0001213900-24-077792 · ownership.xml · nonDerivative · entry 1

Shenouda Maged · CIK 0001658369 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,097

F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.

F2 · price: Purchase prices range from $2.49 to $2.60 per share, inclusive.

Read SEC document
May 24, 2024 Filed May 29, 2024 21:24 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 OtherStock Option (right to buy) · Derivative 54,624 $0.00 Strike: $2.48 $0.00
Disclosure

SEC source: 0001213900-24-047638 · ownership.xml · derivative · entry 2

Shenouda Maged · CIK 0001658369 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,090

Underlying: Common Stock · 54,624 shares

Expires 2033-12-15

F2 · kind: On May 24, 2024, the Reporting Person voluntarily forfeited to the Issuer a portion of the December Award equal to the Additional Award Shares so that those shares can be allocated to the holders of Similar Awards who are not executive officers or directors of the Issuer.

Read SEC document
May 24, 2024 Filed May 29, 2024 21:24 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 GrantStock Option (right to buy) · Derivative 54,624 $0.00 Strike: $2.48 $0.00
Disclosure

SEC source: 0001213900-24-047638 · ownership.xml · derivative · entry 1

Shenouda Maged · CIK 0001658369 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 136,714

Underlying: Common Stock · 54,624 shares

Expires 2033-12-15

F1 · kind: On May 24, 2024, under the terms of the option award granted to the Reporting Person on December 15, 2023 (the "December Award"), the Reporting Person became entitled to receive options for up to 54,624 additional shares of the Issuer's Common Stock on the same terms as the December Award (the "Additional Award Shares") out of shares that had become available under the terms of the Issuer's 2021 Equity Incentive Plan, as amended (the "Plan"), since December 15, 2023, as a result of expirations, cancelations, forfeitures and terminations of other outstanding awards under the Plan and/or tenders or withholding of shares.

Read SEC document
January 31, 2024 Filed Jan 31, 2024 18:28 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 PurchaseCommon Stock 6,875 $4.06 $27,943.44
Disclosure

SEC source: 0001213900-24-008559 · ownership.xml · nonDerivative · entry 3

Shenouda Maged · CIK 0001658369 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,903

F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.

F4 · price: Purchase prices range from $3.95 to $4.18 per share, inclusive.

Read SEC document
January 30, 2024 Filed Jan 31, 2024 18:28 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 PurchaseCommon Stock 15,000 $3.89 $58,323.00
Disclosure

SEC source: 0001213900-24-008559 · ownership.xml · nonDerivative · entry 2

Shenouda Maged · CIK 0001658369 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,028

F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.

F3 · price: Purchase prices range from $3.82 to $3.90 per share, inclusive.

Read SEC document
January 29, 2024 Filed Jan 31, 2024 18:28 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 PurchaseCommon Stock 10,800 $3.65 $39,450.24
Disclosure

SEC source: 0001213900-24-008559 · ownership.xml · nonDerivative · entry 1

Shenouda Maged · CIK 0001658369 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,028

F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.

F2 · price: Purchase prices range from $3.57 to $3.745 per share, inclusive.

Read SEC document
December 15, 2023 Filed Dec 19, 2023 17:28 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 GrantStock Option (right to buy) · Derivative 82,090 $0.00 Strike: $2.48 $0.00
Disclosure

SEC source: 0001213900-23-097031 · ownership.xml · derivative · entry 1

Shenouda Maged · CIK 0001658369 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,090

Underlying: Common Stock · 82,090 shares

Expires 2033-12-15

F1 · derivative.exercise_date: The options vest in 16 equal quarterly installments commencing on March 15, 2024.

Read SEC document
May 25, 2023 Filed May 30, 2023 17:09 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 GrantStock Option (right to buy) · Derivative 317,643 $0.00 Strike: $3.37 $0.00
Disclosure

SEC source: 0001213900-23-044089 · ownership.xml · derivative · entry 1

Shenouda Maged · CIK 0001658369 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 512,560

Underlying: Common Stock · 317,643 shares

Expires 2032-12-16

F1 · date: The option grant was approved by the Board of Directors of the Company on December 16, 2022, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan, as amended (the "Plan"), increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2023, at the 2023 Annual Meeting of the Company's shareholders.

F2 · derivative.exercise_date: 62,560 of the options immediately vested; 450,000 options vest in 16 equal quarterly installments commencing on March 16, 2023.

F2 · balance_after: 62,560 of the options immediately vested; 450,000 options vest in 16 equal quarterly installments commencing on March 16, 2023.

Read SEC document
December 16, 2022 Filed Dec 20, 2022 19:31 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 OtherStock Option (right to buy) · Derivative 200,000 Not disclosed Strike: $19.03 Not disclosed
Disclosure

SEC source: 0001213900-22-081519 · ownership.xml · derivative · entry 1

Shenouda Maged · CIK 0001658369 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common stock · 200,000 shares

Expires 2031-12-17

F1 · kind: Represents the termination of milestone-based stock options granted to the reporting person on May 25, 2022, that were eligible to vest based on achievement of certain corporate objectives by the Issuer. Upon grant, the target vesting amount was reported in Table II of Form 4. On December 16, 2022, the Board of Directors determined that such milestone objectives were not achieved by the Issuer and that all 200,000 options would be terminated.

F1 · shares: Represents the termination of milestone-based stock options granted to the reporting person on May 25, 2022, that were eligible to vest based on achievement of certain corporate objectives by the Issuer. Upon grant, the target vesting amount was reported in Table II of Form 4. On December 16, 2022, the Board of Directors determined that such milestone objectives were not achieved by the Issuer and that all 200,000 options would be terminated.

F2 · price: Not applicable.

F2 · derivative.exercise_date: Not applicable.

F3 · derivative.expiration_date: Original expiration date.

Read SEC document
December 16, 2022 Filed Dec 20, 2022 17:34 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 GrantStock Option (right to buy) · Derivative 194,917 $0.00 Strike: $3.37 $0.00
Disclosure

SEC source: 0001213900-22-081479 · ownership.xml · derivative · entry 1

Shenouda Maged · CIK 0001658369 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 194,917

Underlying: Common Stock · 194,917 shares

Expires 2032-12-16

F1 · derivative.exercise_date: 62,560 of the shares are immediately vested; 132,357 shares vest in 16 equal quarterly installments commencing on March 16, 2023.

Read SEC document
May 25, 2022 Filed May 26, 2022 18:42 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 GrantStock Option (right to buy) · Derivative 200,000 $0.00 Strike: $19.03 $0.00
Disclosure

SEC source: 0001213900-22-029837 · ownership.xml · derivative · entry 2

Shenouda Maged · CIK 0001658369 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2031-12-17

F1 · date: The option grant was approved by the Board of Directors of the Company on December 17, 2021, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan (the "Plan") increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2022, at the 2022 Annual Meeting of the Company's shareholders.

F3 · derivative.exercise_date: 50% of the option shall vest when the Board of Directors or Compensation Committee has determined that 301, 302 and 303 Trials of dextromethadone (REL-1017) in major depressive disorder ("MDD") complete enrollment, as defined in the respective Trial's protocol, with 364 patients per Trial with the last patient in for each trial to be enrolled by December 31, 2022. The remaining 50% of the option shall vest when the Board of Directors or Compensation Committee has determined that 301, 302 and 303 Trials of REL-1017 in MDD report top-line data by December 31, 2023, and meet or exceed their primary and key secondary endpoints as defined in in the respective Trial's protocol.

Read SEC document
May 25, 2022 Filed May 26, 2022 18:42 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 GrantStock Option (right to buy) · Derivative 295,211 $0.00 Strike: $19.03 $0.00
Disclosure

SEC source: 0001213900-22-029837 · ownership.xml · derivative · entry 1

Shenouda Maged · CIK 0001658369 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 522,729

Underlying: Common Stock · 295,211 shares

Expires 2031-12-17

F1 · date: The option grant was approved by the Board of Directors of the Company on December 17, 2021, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan (the "Plan") increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2022, at the 2022 Annual Meeting of the Company's shareholders.

F2 · derivative.exercise_date: The option vests in 16 equal quarterly installments, at 6.25% per quarter, commencing on March 17, 2022.

Read SEC document
December 17, 2021 Filed Dec 21, 2021 21:30 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 GrantStock Option (right to buy) · Derivative 227,518 $0.00 Strike: $19.03 $0.00
Disclosure

SEC source: 0001213900-21-066822 · ownership.xml · derivative · entry 1

Shenouda Maged · CIK 0001658369 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 227,518

Underlying: Common Stock · 227,518 shares

Expires 2031-12-17

F1 · derivative.exercise_date: The option vests in 16 equal quarterly installments commencing on March 17, 2022.

Read SEC document
March 10, 2021 Filed Mar 10, 2021 18:18 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 SaleCommon Stock 2,373 $35.11 $83,313.42
Disclosure

SEC source: 0001213900-21-014656 · ownership.xml · nonDerivative · entry 5

Shenouda Maged · CIK 0001658369 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,228

F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020.

F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F5 · price: Sales prices range from $35.00 to $35.37 per share, inclusive.

Read SEC document
March 09, 2021 Filed Mar 10, 2021 18:18 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 SaleCommon Stock 1,800 $36.02 $64,836.00
Disclosure

SEC source: 0001213900-21-014656 · ownership.xml · nonDerivative · entry 4

Shenouda Maged · CIK 0001658369 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,601

F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020.

F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F4 · price: Sales prices range from $36.02 to $36.51 per share, inclusive.

Read SEC document
March 09, 2021 Filed Mar 10, 2021 18:18 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 SaleCommon Stock 5,727 $35.42 $202,857.21
Disclosure

SEC source: 0001213900-21-014656 · ownership.xml · nonDerivative · entry 3

Shenouda Maged · CIK 0001658369 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,401

F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020.

F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F3 · price: Sales prices range from $35.02 to $35.95 per share, inclusive.

Read SEC document
March 08, 2021 Filed Mar 10, 2021 18:18 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 Exercise / conversionOptions to purchase common stock · Derivative 10,000 $0.00 Strike: $3.24 $0.00
Disclosure

SEC source: 0001213900-21-014656 · ownership.xml · derivative · entry 6

Shenouda Maged · CIK 0001658369 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,350

Underlying: Common Stock · 10,000 shares

Expires 2027-10-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · price: Not applicable

F6 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period.

Read SEC document
March 08, 2021 Filed Mar 10, 2021 18:18 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 SaleCommon Stock 100 $35.00 $3,500.00
Disclosure

SEC source: 0001213900-21-014656 · ownership.xml · nonDerivative · entry 2

Shenouda Maged · CIK 0001658369 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,128

F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020.

Read SEC document
March 08, 2021 Filed Mar 10, 2021 18:18 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 Exercise / conversionCommon Stock 10,000 $3.24 $32,400.00
Disclosure

SEC source: 0001213900-21-014656 · ownership.xml · nonDerivative · entry 1

Shenouda Maged · CIK 0001658369 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,228

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 24, 2021 Filed Feb 26, 2021 16:48 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 Exercise / conversionOptions to purchase common stock · Derivative 3,000 $0.00 Strike: $3.24 $0.00
Disclosure

SEC source: 0001213900-21-012169 · ownership.xml · derivative · entry 4

Shenouda Maged · CIK 0001658369 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,250

Underlying: Common Stock · 3,000 shares

Expires 2027-10-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · price: Not applicable

F5 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period.

Read SEC document
February 24, 2021 Filed Feb 26, 2021 16:48 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 SaleCommon Stock 1,400 $34.67 $48,544.44
Disclosure

SEC source: 0001213900-21-012169 · ownership.xml · nonDerivative · entry 3

Shenouda Maged · CIK 0001658369 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,228

F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020.

F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F4 · price: Sales prices range from $34.47 to $35.03 per share, inclusive.

Read SEC document
February 24, 2021 Filed Feb 26, 2021 16:48 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 SaleCommon Stock 1,600 $33.74 $53,984.80
Disclosure

SEC source: 0001213900-21-012169 · ownership.xml · nonDerivative · entry 2

Shenouda Maged · CIK 0001658369 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,628

F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020.

F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F3 · price: Sales prices range from $33.35 to $34.30 per share, inclusive.

Read SEC document
February 24, 2021 Filed Feb 26, 2021 16:48 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 Exercise / conversionCommon Stock 3,000 $3.24 $9,720.00
Disclosure

SEC source: 0001213900-21-012169 · ownership.xml · nonDerivative · entry 1

Shenouda Maged · CIK 0001658369 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,228

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 11, 2021 Filed Feb 16, 2021 17:08 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 Exercise / conversionOptions to purchase common stock · Derivative 1,428 $0.00 Strike: $3.24 $0.00
Disclosure

SEC source: 0001213900-21-009696 · ownership.xml · derivative · entry 3

Shenouda Maged · CIK 0001658369 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,250

Underlying: Common Stock · 1,428 shares

Expires 2027-10-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · price: Not applicable

F4 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period.

Read SEC document
February 11, 2021 Filed Feb 16, 2021 17:08 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 SaleCommon Stock 1,428 $35.39 $50,542.06
Disclosure

SEC source: 0001213900-21-009696 · ownership.xml · nonDerivative · entry 2

Shenouda Maged · CIK 0001658369 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,228

F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020.

F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F3 · price: Sales prices range from $35.12 to $35.96 per share, inclusive.

Read SEC document
February 11, 2021 Filed Feb 16, 2021 17:08 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 Exercise / conversionCommon Stock 1,428 $3.24 $4,626.72
Disclosure

SEC source: 0001213900-21-009696 · ownership.xml · nonDerivative · entry 1

Shenouda Maged · CIK 0001658369 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,656

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 10, 2021 Filed Feb 10, 2021 19:25 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 SaleCommon Stock 2,410 $35.20 $84,825.49
Disclosure

SEC source: 0001213900-21-008202 · ownership.xml · nonDerivative · entry 4

Shenouda Maged · CIK 0001658369 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,228

F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020.

F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F5 · price: Sales prices range from $35.00 to $35.64 per share, inclusive

Read SEC document
February 09, 2021 Filed Feb 10, 2021 19:25 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 SaleCommon Stock 5,359 $35.24 $188,843.12
Disclosure

SEC source: 0001213900-21-008202 · ownership.xml · nonDerivative · entry 3

Shenouda Maged · CIK 0001658369 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,638

F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020.

F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F4 · price: Sales prices range from $35.00 to $35.82 per share, inclusive

Read SEC document
February 08, 2021 Filed Feb 10, 2021 19:25 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 Exercise / conversionOptions to purchase common stock · Derivative 11,372 $0.00 Strike: $3.24 $0.00
Disclosure

SEC source: 0001213900-21-008202 · ownership.xml · derivative · entry 5

Shenouda Maged · CIK 0001658369 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,678

Underlying: Common Stock · 11,372 shares

Expires 2027-10-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · price: Not applicable

F6 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period.

Read SEC document
February 08, 2021 Filed Feb 10, 2021 19:25 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 SaleCommon Stock 3,603 $35.04 $126,241.55
Disclosure

SEC source: 0001213900-21-008202 · ownership.xml · nonDerivative · entry 2

Shenouda Maged · CIK 0001658369 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,997

F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020.

F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F3 · price: Sales prices range from $35.00 to $35.29 per share, inclusive.

Read SEC document
February 08, 2021 Filed Feb 10, 2021 19:25 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 Exercise / conversionCommon Stock 11,372 $3.24 $36,845.28
Disclosure

SEC source: 0001213900-21-008202 · ownership.xml · nonDerivative · entry 1

Shenouda Maged · CIK 0001658369 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,600

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 03, 2021 Filed Feb 4, 2021 17:38 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 SaleCommon Stock 100 $35.00 $3,500.00
Disclosure

SEC source: 0001213900-21-006832 · ownership.xml · nonDerivative · entry 3

Shenouda Maged · CIK 0001658369 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,228

F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020.

F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

Read SEC document
February 02, 2021 Filed Feb 4, 2021 17:38 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 Exercise / conversionOptions to purchase common stock · Derivative 3,200 $0.00 Strike: $3.24 $0.00
Disclosure

SEC source: 0001213900-21-006832 · ownership.xml · derivative · entry 4

Shenouda Maged · CIK 0001658369 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,050

Underlying: Common Stock · 3,200 shares

Expires 2027-10-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · price: Not applicable

F4 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period.

Read SEC document
February 02, 2021 Filed Feb 4, 2021 17:38 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 SaleCommon Stock 3,100 $35.04 $108,633.92
Disclosure

SEC source: 0001213900-21-006832 · ownership.xml · nonDerivative · entry 2

Shenouda Maged · CIK 0001658369 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,328

F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020.

F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F3 · price: Sales prices range from $35.00 to $35.21 per share, inclusive.

Read SEC document
February 02, 2021 Filed Feb 4, 2021 17:38 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 Exercise / conversionCommon Stock 3,200 $3.24 $10,368.00
Disclosure

SEC source: 0001213900-21-006832 · ownership.xml · nonDerivative · entry 1

Shenouda Maged · CIK 0001658369 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,428

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 27, 2021 Filed Jan 29, 2021 17:24 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 Exercise / conversionOptions to purchase common stock · Derivative 3,000 $0.00 Strike: $3.24 $0.00
Disclosure

SEC source: 0001213900-21-005451 · ownership.xml · derivative · entry 4

Shenouda Maged · CIK 0001658369 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,250

Underlying: Common Stock · 3,000 shares

Expires 2027-10-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · price: Not applicable

F5 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period.

Read SEC document
January 27, 2021 Filed Jan 29, 2021 17:24 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 SaleCommon Stock 1,200 $32.43 $38,916.00
Disclosure

SEC source: 0001213900-21-005451 · ownership.xml · nonDerivative · entry 3

Shenouda Maged · CIK 0001658369 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,228

F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020.

F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F4 · price: Sales prices range from $32.66 to $33.43 per share, inclusive.

Read SEC document
January 27, 2021 Filed Jan 29, 2021 17:24 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 SaleCommon Stock 1,800 $31.59 $56,862.00
Disclosure

SEC source: 0001213900-21-005451 · ownership.xml · nonDerivative · entry 2

Shenouda Maged · CIK 0001658369 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,428

F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020.

F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F3 · price: Sales prices range from $31.59 to $32.50 per share, inclusive.

Read SEC document
January 27, 2021 Filed Jan 29, 2021 17:24 UTC RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 Exercise / conversionCommon Stock 3,000 $3.24 $9,720.00
Disclosure

SEC source: 0001213900-21-005451 · ownership.xml · nonDerivative · entry 1

Shenouda Maged · CIK 0001658369 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,228

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.